CA2584481C - Pharmaceutical compositions based on nk2 antagonists for pediatric use - Google Patents
Pharmaceutical compositions based on nk2 antagonists for pediatric use Download PDFInfo
- Publication number
- CA2584481C CA2584481C CA2584481A CA2584481A CA2584481C CA 2584481 C CA2584481 C CA 2584481C CA 2584481 A CA2584481 A CA 2584481A CA 2584481 A CA2584481 A CA 2584481A CA 2584481 C CA2584481 C CA 2584481C
- Authority
- CA
- Canada
- Prior art keywords
- beta
- cyclo
- dap
- trp
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 239000005557 antagonist Substances 0.000 title abstract description 23
- 208000002881 Colic Diseases 0.000 claims abstract description 20
- 206010021746 Infantile colic Diseases 0.000 claims abstract description 18
- 239000002462 tachykinin receptor antagonist Substances 0.000 claims description 13
- 239000002746 neurokinin 2 receptor antagonist Substances 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims 3
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 108010092101 MEN 11420 Proteins 0.000 description 13
- NGCNKEZHGRXHNL-WVWQGFTISA-N n-[(2r,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-2-[(1s,4s,7s,10s,13s,16s)-13-benzyl-16-(1h-indol-3-ylmethyl)-7-(2-methylpropyl)-3,6,9,12,15,18,20-heptaoxo-2,5,8,11,14,17,21-heptazabicyclo[8.8.4]docosan-4-yl]acetamide Chemical compound C([C@H]1C(=O)N[C@H]2CC(=O)NC[C@H](NC(=O)[C@H](CC=3C=CC=CC=3)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC2=O)C(=O)N[C@H](C(N1)=O)CC(C)C)C(=O)N[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O NGCNKEZHGRXHNL-WVWQGFTISA-N 0.000 description 13
- 229950000640 nepadutant Drugs 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 208000002551 irritable bowel syndrome Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102000003141 Tachykinin Human genes 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 108060008037 tachykinin Proteins 0.000 description 7
- 230000009278 visceral effect Effects 0.000 description 6
- 239000000556 agonist Substances 0.000 description 5
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 5
- -1 polysiloxanes Polymers 0.000 description 5
- 235000010199 sorbic acid Nutrition 0.000 description 5
- 229940075582 sorbic acid Drugs 0.000 description 5
- 239000004334 sorbic acid Substances 0.000 description 5
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- 208000035154 Hyperesthesia Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 235000011034 Rubus glaucus Nutrition 0.000 description 3
- 244000235659 Rubus idaeus Species 0.000 description 3
- 235000009122 Rubus idaeus Nutrition 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- PGKXDIMONUAMFR-AREMUKBSSA-N saredutant Chemical compound C([C@H](CN(C)C(=O)C=1C=CC=CC=1)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1(NC(C)=O)C1=CC=CC=C1 PGKXDIMONUAMFR-AREMUKBSSA-N 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 102100024304 Protachykinin-1 Human genes 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- 102100037342 Substance-K receptor Human genes 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000008991 intestinal motility Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- RMRHFQVHSFCBEO-UHFFFAOYSA-N n-[2-(3,4-dichlorophenyl)-4-(3-oxospiro[2,4-dihydroisoquinoline-1,4'-piperidine]-1'-yl)butyl]-3,4,5-trimethoxy-n-methylbenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N(C)CC(CCN2CCC3(CC2)C2=CC=CC=C2CC(=O)N3)C=2C=C(Cl)C(Cl)=CC=2)=C1 RMRHFQVHSFCBEO-UHFFFAOYSA-N 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- KZKYRHRAVGWEAV-UHFFFAOYSA-N 2,3-dichlorobenzamide Chemical compound NC(=O)C1=CC=CC(Cl)=C1Cl KZKYRHRAVGWEAV-UHFFFAOYSA-N 0.000 description 1
- QNLIUVLFRVYNCV-XIFFEERXSA-N 3-[1-[2-[(2r)-4-benzoyl-2-(3,4-difluorophenyl)morpholin-2-yl]ethyl]-4-phenylpiperidin-4-yl]-1,1-dimethylurea Chemical compound C([C@@](OCC1)(CCN2CCC(CC2)(NC(=O)N(C)C)C=2C=CC=CC=2)C=2C=C(F)C(F)=CC=2)N1C(=O)C1=CC=CC=C1 QNLIUVLFRVYNCV-XIFFEERXSA-N 0.000 description 1
- OQXJUJDDCWHRLA-XMMPIXPASA-N 4-[1-[2-[(3s)-1-(cyclopropylmethyl)-3-(3,4-dichlorophenyl)-6-oxopiperidin-3-yl]ethyl]azetidin-3-yl]piperazine-1-sulfonamide Chemical compound C1CN(S(=O)(=O)N)CCN1C1CN(CC[C@]2(CN(CC3CC3)C(=O)CC2)C=2C=C(Cl)C(Cl)=CC=2)C1 OQXJUJDDCWHRLA-XMMPIXPASA-N 0.000 description 1
- KQRBOHOKLNORTA-UHFFFAOYSA-N 6-methyl-1-benzothiophene-2-carboxylic acid Chemical compound CC1=CC=C2C=C(C(O)=O)SC2=C1 KQRBOHOKLNORTA-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 101800000399 Neurokinin A Proteins 0.000 description 1
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 1
- 102400000097 Neurokinin A Human genes 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010038731 Respiratory tract irritation Diseases 0.000 description 1
- 108010083785 TAC 363 Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000002741 bronchospastic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 230000004090 etiopathogenesis Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000021129 infant diet Nutrition 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- RTUNBOPBBCULLC-DEOSSOPVSA-N n-[(2s)-3,3-dimethylbutan-2-yl]-2-phenyl-3-[(4-piperidin-1-ylpiperidin-1-yl)methyl]quinoline-4-carboxamide Chemical compound C=1C=CC=CC=1C1=NC2=CC=CC=C2C(C(=O)N[C@@H](C)C(C)(C)C)=C1CN(CC1)CCC1N1CCCCC1 RTUNBOPBBCULLC-DEOSSOPVSA-N 0.000 description 1
- BHCJHYIMNHXLOM-WVDRJWPYSA-N n-[(e,2r)-1-(3,4-dichlorophenyl)-5-oxo-5-[[(3r)-2-oxoazepan-3-yl]amino]pent-3-en-2-yl]-n-methyl-3,5-bis(trifluoromethyl)benzamide Chemical compound C([C@@H](N(C)C(=O)C=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)\C=C\C(=O)N[C@H]1C(NCCCC1)=O)C1=CC=C(Cl)C(Cl)=C1 BHCJHYIMNHXLOM-WVDRJWPYSA-N 0.000 description 1
- 239000002744 neurokinin 2 receptor agonist Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002325 prokinetic agent Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LEWDKQKVAFOMPI-UHFFFAOYSA-N quinoline-4-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CC=NC2=C1 LEWDKQKVAFOMPI-UHFFFAOYSA-N 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229950004387 saredutant Drugs 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITFI2004A000221 | 2004-10-27 | ||
| IT000221A ITFI20040221A1 (it) | 2004-10-27 | 2004-10-27 | Composizioni farmaceutiche a base di nk2 antagonisti per uso pediatrico |
| PCT/EP2005/055575 WO2006045820A1 (en) | 2004-10-27 | 2005-10-26 | Pharmaceutical compositions based on nk2 antagonists for pediatric use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2584481A1 CA2584481A1 (en) | 2006-05-04 |
| CA2584481C true CA2584481C (en) | 2014-07-15 |
Family
ID=35613882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2584481A Expired - Fee Related CA2584481C (en) | 2004-10-27 | 2005-10-26 | Pharmaceutical compositions based on nk2 antagonists for pediatric use |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7727955B2 (enExample) |
| EP (1) | EP1809267B1 (enExample) |
| JP (1) | JP2008517977A (enExample) |
| CN (1) | CN101052386A (enExample) |
| AR (1) | AR051595A1 (enExample) |
| AT (1) | ATE422881T1 (enExample) |
| AU (1) | AU2005298629B2 (enExample) |
| CA (1) | CA2584481C (enExample) |
| CY (1) | CY1109803T1 (enExample) |
| DE (1) | DE602005012857D1 (enExample) |
| DK (1) | DK1809267T3 (enExample) |
| EA (1) | EA012264B1 (enExample) |
| ES (1) | ES2325413T3 (enExample) |
| HR (1) | HRP20090225T1 (enExample) |
| IT (1) | ITFI20040221A1 (enExample) |
| MX (1) | MX2007004461A (enExample) |
| NO (1) | NO338586B1 (enExample) |
| NZ (1) | NZ555380A (enExample) |
| PL (1) | PL1809267T3 (enExample) |
| PT (1) | PT1809267E (enExample) |
| RS (1) | RS50780B (enExample) |
| SI (1) | SI1809267T1 (enExample) |
| UA (1) | UA91988C2 (enExample) |
| WO (1) | WO2006045820A1 (enExample) |
| ZA (1) | ZA200703909B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0614970D0 (en) * | 2006-07-27 | 2006-09-06 | R & D Sosei Ltd | Compounds For Use In Therapy |
| IT1394304B1 (it) * | 2009-05-21 | 2012-06-06 | Malesci Sas | Processo per la preparazione di ibodutant (men15596) e relativi intermedi |
| ITRM20120331A1 (it) * | 2012-07-12 | 2014-01-13 | Guidotti & C Spa Labor | Composizioni pediatriche orali liquide contenenti nepadutant. |
| US20160051596A1 (en) * | 2014-08-21 | 2016-02-25 | Food Industry Research And Development Institute | Novel acetobacter and gluconacetobacter strains and their metabolites for use in inhibiting xanthine oxidase |
| US9867857B2 (en) | 2014-08-21 | 2018-01-16 | Food Industry Research And Development Institute | Acetobacter and gluconacetobacter strains and their metabolites for use in inhibiting xanthine oxidase |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0219318A (ja) * | 1988-06-30 | 1990-01-23 | Carl R Thornfeldt | 疝痛及び生歯に対する治療 |
| IT1277835B1 (it) * | 1995-03-13 | 1997-11-12 | Menarini Farma Ind | Composti biciclici, loro preparazione ed uso in composizioni farmaceutiche |
| IT1307809B1 (it) * | 1999-10-21 | 2001-11-19 | Menarini Ricerche Spa | Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono. |
| MY130373A (en) * | 2001-10-29 | 2007-06-29 | Malesci Sas | Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| GB0224788D0 (en) * | 2002-10-24 | 2002-12-04 | Novartis Ag | Organic compounds |
-
2004
- 2004-10-27 IT IT000221A patent/ITFI20040221A1/it unknown
-
2005
- 2005-10-24 AR ARP050104429A patent/AR051595A1/es unknown
- 2005-10-26 CA CA2584481A patent/CA2584481C/en not_active Expired - Fee Related
- 2005-10-26 DK DK05810894T patent/DK1809267T3/da active
- 2005-10-26 RS RSP-2009/0169A patent/RS50780B/sr unknown
- 2005-10-26 ES ES05810894T patent/ES2325413T3/es not_active Expired - Lifetime
- 2005-10-26 EP EP05810894A patent/EP1809267B1/en not_active Expired - Lifetime
- 2005-10-26 JP JP2007538414A patent/JP2008517977A/ja active Pending
- 2005-10-26 PL PL05810894T patent/PL1809267T3/pl unknown
- 2005-10-26 EA EA200700949A patent/EA012264B1/ru not_active IP Right Cessation
- 2005-10-26 AU AU2005298629A patent/AU2005298629B2/en not_active Ceased
- 2005-10-26 SI SI200530661T patent/SI1809267T1/sl unknown
- 2005-10-26 US US11/666,204 patent/US7727955B2/en not_active Expired - Fee Related
- 2005-10-26 WO PCT/EP2005/055575 patent/WO2006045820A1/en not_active Ceased
- 2005-10-26 UA UAA200705837A patent/UA91988C2/ru unknown
- 2005-10-26 MX MX2007004461A patent/MX2007004461A/es active IP Right Grant
- 2005-10-26 HR HR20090225T patent/HRP20090225T1/xx unknown
- 2005-10-26 PT PT05810894T patent/PT1809267E/pt unknown
- 2005-10-26 AT AT05810894T patent/ATE422881T1/de active
- 2005-10-26 NZ NZ555380A patent/NZ555380A/en not_active IP Right Cessation
- 2005-10-26 CN CNA2005800370703A patent/CN101052386A/zh active Pending
- 2005-10-26 DE DE602005012857T patent/DE602005012857D1/de not_active Expired - Lifetime
-
2007
- 2007-05-15 ZA ZA200703909A patent/ZA200703909B/xx unknown
- 2007-05-29 NO NO20072720A patent/NO338586B1/no not_active IP Right Cessation
-
2009
- 2009-05-07 CY CY20091100493T patent/CY1109803T1/el unknown
-
2010
- 2010-04-19 US US12/799,176 patent/US20100234284A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20072720L (no) | 2007-07-09 |
| US20080090795A1 (en) | 2008-04-17 |
| CN101052386A (zh) | 2007-10-10 |
| EA200700949A1 (ru) | 2007-10-26 |
| ITFI20040221A1 (it) | 2005-01-27 |
| ATE422881T1 (de) | 2009-03-15 |
| NO338586B1 (no) | 2016-09-12 |
| HRP20090225T1 (hr) | 2009-05-31 |
| EP1809267B1 (en) | 2009-02-18 |
| RS50780B (sr) | 2010-08-31 |
| CY1109803T1 (el) | 2014-09-10 |
| EP1809267A1 (en) | 2007-07-25 |
| PT1809267E (pt) | 2009-05-28 |
| DE602005012857D1 (de) | 2009-04-02 |
| SI1809267T1 (sl) | 2009-06-30 |
| AU2005298629B2 (en) | 2011-02-17 |
| MX2007004461A (es) | 2007-07-11 |
| ZA200703909B (en) | 2008-09-25 |
| UA91988C2 (ru) | 2010-09-27 |
| DK1809267T3 (da) | 2009-05-18 |
| AU2005298629A1 (en) | 2006-05-04 |
| PL1809267T3 (pl) | 2009-07-31 |
| US20100234284A1 (en) | 2010-09-16 |
| ES2325413T3 (es) | 2009-09-03 |
| HK1109335A1 (en) | 2008-06-06 |
| US7727955B2 (en) | 2010-06-01 |
| WO2006045820A1 (en) | 2006-05-04 |
| JP2008517977A (ja) | 2008-05-29 |
| EA012264B1 (ru) | 2009-08-28 |
| NZ555380A (en) | 2008-12-24 |
| CA2584481A1 (en) | 2006-05-04 |
| AR051595A1 (es) | 2007-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI361693B (en) | Novel use of peptide compounds for treating essential tremor and other tremor syndromes | |
| HUT76852A (en) | Use of benzotiophene derivatives for production of pharmaceutical compositions useful for inhibiting conditions associated with neuro-peptide y | |
| WO2008139984A1 (en) | Cinnamide compounds for dementia | |
| US20100234284A1 (en) | Pharmaceutical compositions based on NK2 antagonists for pediatric use | |
| WO1997041878A1 (en) | Treatment of mood disorders with a growth hormone secretagogue | |
| CN102316872A (zh) | 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂 | |
| ES2971063T3 (es) | Nuevos usos terapéuticos de ligandos H3 | |
| CA2253390A1 (en) | Enhancement of sleep with a growth hormone secretagogue | |
| AU2017315265C1 (en) | Method for treating pruritus and/or itch | |
| WO2003006019A1 (fr) | Composition medicinale destinee au traitement de la cystite interstitielle | |
| JP2002500651A (ja) | 精神分裂病及び精神病の治療方法 | |
| JP2002525274A (ja) | 成長ホルモン分泌促進剤による独立生活状況への復帰促進 | |
| EP1872795A1 (en) | Therapeutic agent for irritable bowel syndrome | |
| BR112019021125A2 (pt) | Combinação de antagonista de nk1 e método para tratamento de sinucleinopatias | |
| JP2008525413A (ja) | 双極性障害を治療するための単剤としてのサブコメリン、または、気分安定剤または抗躁病薬と併用されるサブコメリン | |
| HK1109335B (en) | Pharmaceutical compositions based on nk2 antagonists for pediatric use | |
| JP2022502441A (ja) | Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物 | |
| HK40013330B (en) | New therapeutical use of h3-ligands | |
| JPH1192376A (ja) | ニコチン依存症治療剤 | |
| EA044055B1 (ru) | Применение антагониста рецептора нейрокинина-3 (nk-3) для повышения уровней циркулирующего лептина у пациентов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20191028 |